Magstim CEO Lothar Krinke, PhD discusses Magstim and opportunities in transcranial magnetic stimulation in an interview with SmartTRAK

As a pioneer in transcranial magnetic stimulation (TMS), Magstim has been a leading supplier of transcranial magnetic stimulators for the last 30 years. Although TMS was first primarily used for research applications, it is now widely used in the clinical setting as a non-invasive therapy to treat major depressive disorder in patients who have failed medication therapy or other treatments. Magstim estimates approximately 50,000+ patients per year in the US receive TMS therapy for depression, a fraction of the five-to-six million patients who currently suffer from medication-resistant depression. 

The combined worldwide market for TMS, including the clinical and research market, is estimated at ~$200 million a year, but it is potentially a multi-billion dollar market according to Magstim CEO Lothar Krinke, PhD. To find out more about TMS and Magstim, including its recent acquisition of Electrical Geodesics (EGI) and its high-density EEG from Royal Philips, click on the following video to listen to SmartTRAK’s interview with Dr. Krinke, recorded live via Uberconference (31:05 min). To download a complete transcript of the interview, just click the link below.

Charlie Covert, VP/GM of Medtronic’s Pain Therapies business, discusses 12-month follow up data from the DTM SCS RCT, orchestrating the neuro-glial response and much more in an interview with SmartTRAK.

Charlie Covert, VP/GM of Medtronic’s Pain Therapies business discusses 12-month data from the Company’s Differential Targeted Multiplexed (DTM) SCS RCT, why they used a modified intent to treat analysis (mITT) and what’s next for DTM research in an interview with   SmartTRAK.

To find out more about DTM SCS, including its mechanism of action (MOA), how it’s doing in the market and Medtronics’ research into expanded indications and new technologies, click the link below to download the complete transcript of the interview.

In the market for Peripheral Nerve Stimulation (PNS), companies are developing new wireless or minimally invasive technologies with novel waveforms and form factors designed to treat a wide variety of applications and unmet clinical needs, including for the treatment of intractable migraines, chronic intractable postoperative pain, suprascapular neuralgia, low back pain, tibial/ankle pain, stroke rehab, overactive bladder and tibial nerve stimulation, to name a few.

Companies competing in the market for PNS include Stimwave Technologies*, Nalu Medical*, SPR Therapeutics, Bioness and Cala Health among others. To find out more about these companies and what’s new for PNS, SmartTRAK highlights market updates covering the top news, clinical studies, reimbursement and patents in PNS so far in 2020.

MedTech Strategist reported that In May of this year, the Deloitte Center for Health Solutions conducted "an online survey of 50 clinical and service line leaders at US provider organizations on their deferred procedures". With the return of elective procedures being integral to a comeback for the MedTech industry, the results of that survey suggest that the path to resuming these procedures is becoming more complicated.

According to the Deloitte survey, "Respondents expect the return to pre-COVID-19 productivity volumes to take two to six months, with three months the typical estimate. When asked to list their top concerns about resuming deferred procedures, providers say a second coronavirus outbreak is their biggest worry (82%)". It appears that their biggest fear, a COVID-19 resurgence, may be coming to pass.

The following is just a small sampling of recent updates regarding the Life Sciences industry's COVID-related delayed procedures and what an impact a resurgence may have. These updates are compiled, reviewed and posted in real-time by our SmartTRAK analysts, who are constantly monitoring the situation and sifting through the noise to present the most relevant news to our subscribers:

COVID-19 hit the SCS market hard in Q220 as shutdowns and widespread procedure cancellations led to a dramatic decline in SCS revenues.

COVID-19 clobbered the SCS market in Q220 as shutdowns and widespread procedure cancellations led to a dramatic decline in SCS revenues, with the biggest impact in April across all geographies. For Q220, WW SCS revenues tumbled down -38.1% vs Q219, and US SCS revenue dropped by -37.7% YoY according to SmartTRAK Financial Dashboard.

Among the many topics covered in the comprehensive Q220 SCS Market Recap* are:

With plans to become a stroke strategic, Imperative Care Chairman and CEO Fred Khosravi discusses elevating stroke care through technology and streamlined care in an interview with SmartTRAK

With plans to become a stroke strategic and leader in in the market for neurovascular products, Imperative Care Chairman and CEO Fred Khosravi says Imperative Care is a clinically driven company focused on elevating stroke care by bringing innovation to the market that addresses unmet clinical needs, expands patient access, democratizes the delivery of care and improves first pass efficiency.

The Company secured $85MM in Series C financing in December 2019 and has introduced two new products to the marketplace--the Zoom Aspiration System and the TracStar LDP (large distal platform), a new category of intracranial access device that combines the stability of a long sheath with the flexibility of an intermediate catheter. According to Khosravi, TracStar LDP (0.088” inner lumen) is capable of reaching farther into the brain than other access devices (to the base of the middle cerebral artery), a feat that allows interventionalists to track farther and get closer to the treatment site for both ischemic and hemorrhagic stroke procedures.

To find out more about these new products, how Imperative Care is faring amid COVID-19 and the Company’s plans for 2020 and beyond, SmartTRAK recently sat down with Khosravi for a wide-ranging interview conducted via Uberconference. To listen to a recording of the interview, click on the following video (48:15 minutes). Specific interview topics by timecode are also outlined below as is a link to download the complete transcript.

Mark Dickinson, Worldwide President of Cerenovus, discusses the Company’s focus on patients, innovation and physicians and becoming a key player in the market for stroke devices in a recent interview with SmartTRAK.

To find out more about Cerenovus, its latest innovations and the Company’s strategies for growth, click on the following video to listen to the interview recorded via Uberconference. (31:11 minutes)  Specific interview topics by timecode are also outlined below.

To download a complete transcript of the interview, click here.

Keith Boettiger, Vice President, Neuromodulation, Abbott discusses COVID-19 and the Company’s strategies for growth in an interview with SmartTRAK

Keith Boettiger, Vice President, Neuromodulation, Abbott discusses how COVID-19 has impacted the Company, its growth strategies, the market for neuromodulation and what’s next in terms of innovation in an interview with SmartTRAK.

To find out more about Abbott and the Company’s latest initiatives, including digital health, remote care and remote programming, click on the following video below to listen to the interview recorded live via Uberconference (35:38 min). Specific interview topics by time code are also outlined below. To download a complete transcript of the interview, click here.

J Mocco, MD, MS discusses how an evolving pandemic is affecting stroke care in an interview with SmartTRAK

The COVID-19 pandemic has dramatically disrupted health care around the world and is wreaking havoc on medical device markets. In the US, social distancing and other mitigation efforts have helped flatten the curve and many states are now working toward reopening their economies.

The pandemic continues to evolve and its impact on healthcare delivery systems is rapidly changing. Elective surgery has re-started again in many states and hard-hit places like New York City have seen COVID-19 cases peak and start to trend downward. So how are these trends affecting stroke care? Why are strokes up in some regions but down in others? When will neurointerventional procedure volumes return to pre-COVID levels? To find out the answers to these questions and more, SmartTRAK talked with J Mocco, MD, MS, Vice Chair, Department of Neurosurgery and Professor of Neurosurgery at Mount Sinai Health System in New York City.

To listen to the interview recorded via Uberconference on Monday May 11, click on the following video. A transcript of the interview can be downloaded here.

The SCS market saw double-digit declines in Q120 as elective procedures fell off a cliff toward the end of the quarter due to COVID-19

After a disappointing slowdown in 2019, the spinal cord stimulation (SCS) market was positioned for growth in Q120 after a successful North American Neuromodulation Society (NANS) Annual Meeting in January 2020. With new data and products providing an early tailwind for all SCS competitors, companies reported positive momentum until approximately the third week of March when COVID-19 led to shelter-in-place orders and a sharp decline in elective procedures. This effectively put a halt to the vast majority of SCS trials and implants in the US and also impacted companies with SCS sales in China during January and February ...

Among the many topics covered in the comprehensive Q120 Spinal Cord Stimulation (SCS) Market Recap* are: